Chemistry:Enarodustat

Short description: Chemical compound

Enarodustat

Clinical data
Trade names	Enaroy
Other names	JTZ-951
Legal status
Legal status	Rx-only (Japan)
Identifiers
IUPAC name 2-{[7-Hydroxy-5-(2-phenylethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]formamido}acetic acid
CAS Number	1262132-81-9
PubChem CID	50899324
DrugBank	14985
ChemSpider	64835234
UNII	JSK7TUA223
KEGG	D11523
ChEMBL	ChEMBL4297619
Chemical and physical data
Formula	C17H16N4O4
Molar mass	340.339 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O
InChI InChI=1S/C17H16N4O4/c22-13-8-12(7-6-11-4-2-1-3-5-11)21-16(19-10-20-21)15(13)17(25)18-9-14(23)24/h1-5,8,10H,6-7,9H2,(H,18,25)(H,19,20)(H,23,24) Key:FJYRBJKWDXVHHO-UHFFFAOYSA-N

Enarodustat (development code JTZ-951; brand name Enaroy) is a drug used for the treatment of anemia, especially when associated with chronic kidney disease (CKD). Enarodustat functions as a inhibitor of hypoxia inducible factor-proly hydroxylase (HIF-PH).

The drug was approved in September 2020 in Japan for anemia associated with CKD and is currently in clinical development in the United States and South Korea. The drug is being developed by Japan Tobacco and JW Pharmaceutical.